Inhibikase Therapeutics Inc SEC Filings

Inhibikase Therapeutics, Inc. (IKT) has filed an amended Form 4 (Form 4/A) for Chief Executive Officer and Director Mark T. Iwicki. The sole purpose of the amendment is to correct two data points that were misstated in the original Form 4 filed on 25 Feb 2025: (i) the exercise price of a stock-option award and (ii) its expiration date.

Key terms of the option grant (originally awarded 21 Feb 2025):

• Derivative security: Non-qualified stock option to purchase 602,346 shares of common stock.
• Corrected exercise price: $2.97 per share.
• Corrected expiration date: 21 Feb 2035 (10-year term).
• Vesting schedule: 48 substantially equal monthly installments beginning 21 Mar 2025, contingent on continued employment.
• Ownership status: Shares are held directly by the reporting person.

The filing does not report new purchases or sales of shares; it is an administrative correction. Nevertheless, the option grant, if fully exercised, would result in issuance of up to 602,346 new shares, creating a modest potential dilution for existing shareholders. Because the option vests over four years, dilution would be gradual and contingent on share-price appreciation above $2.97.

Investor takeaways: (1) Management has rectified an earlier clerical error, demonstrating regulatory compliance; (2) the CEO’s long-term incentive package now has confirmed terms, aligning his interests with shareholders; (3) no immediate cash outflow or revenue impact is associated with the amendment.

Amended Form 4 highlights — Inhibikase Therapeutics (IKT) director Vincent Aurentz filed a Form 4/A dated 07/02/2025 to correct the exercise price of a previously reported option grant.

• Instrument: Stock option for 134,427 common shares.
• Corrected exercise price: $2.97 per share (previous filing reported an incorrect price).
• Grant date: 02/21/2025  |  Expiration: 02/21/2035.
• Vesting schedule: 50% on the first anniversary and 50% on the second anniversary of the grant date, contingent on continued service.
• Ownership form: Direct; no shares were bought or sold in the open market, so the company’s share count and public float are unchanged.

This filing is administrative in nature, rectifying a clerical error. It does not indicate any change in the director’s net exposure or signal new information about Inhibikase’s operations or financial outlook.

On June 30, 2025, Inhibikase Therapeutics, Inc. (IKT) filed a Form 4 reporting that Director Vincent Aurentz received a stock option covering 108,176 common shares at an exercise price of $1.95 per share. The option vests on the earlier of June 30, 2026 or the day prior to the next annual shareholders meeting, provided the director remains in service, and expires on June 30, 2032. After the grant, Mr. Aurentz beneficially owns 108,176 derivative securities and reported no transactions in directly held common stock. The transaction was coded “A” (acquisition), indicating a routine equity award under the company’s director compensation program, with no cash paid and no shares sold.

Form 4 filing for The Walt Disney Company (DIS) reports that director Maria Elena Lagomasino acquired an aggregate 784.9 Disney common shares on 06/30/2025 at a reference price of $119.43 per share. The shares consist of:

• 282.5 stock units received in lieu of quarterly cash board-retainer fees
• 502.4 deferred stock units issued as the regular quarterly grant under Disney’s Amended & Restated 2011 Stock Incentive Plan

Netflix, Inc. (NFLX) – Form 4 filing dated 07/02/2025 discloses multiple option exercises and related sales by Chief Financial Officer Spencer Neumann on 07/01/2025 under a Rule 10b5-1 trading plan adopted 10/29/2024.

• Options exercised: 696 shares at an exercise price of $289.29 and 1,905 shares at $309.99 (total 2,601 shares).
• Open-market sales: The same 2,601 shares were sold in 17 individual trades at prices ranging from $1,283.72 to $1,337.05.
• Net share balance: Beneficial ownership returned to the pre-exercise level of 3,691 common shares held directly.
• Remaining derivatives: 2,905 in-the-money options (exercise price $289.29) remain outstanding and expire 09/03/2029; the second option grant (exercise price $309.99) is now fully exercised.
• No other equity awards or indirect holdings were reported.

The activity represents a cashless exercise—conversion of low-priced options followed by immediate sale of equivalent shares—providing personal liquidity while keeping the CFO’s direct ownership unchanged. Because transactions were pre-scheduled under a 10b5-1 plan, they are generally viewed as routine and do not, on their own, signal a strategic shift or performance concern for Netflix.

Form 4 filing overview: On 06/30/2025, Inhibikase Therapeutics, Inc. (IKT) granted Director Arvind Kush a stock option for 108,176 shares of common stock at an exercise price of $1.95 per share. The option is classified as a derivative security and is held directly by the reporting person.

Vesting & expiration: The option vests on the earlier of (i) June 30, 2026 or (ii) the day before the company’s next annual shareholder meeting, provided the director remains in service through that date. It expires on 06/30/2032.

Post-grant ownership: Following the transaction, Kush beneficially owns 108,176 derivative securities (options) with no change in non-derivative share holdings disclosed. No shares were sold or disposed of in this filing.

Key takeaway: The filing reflects routine director compensation, increasing insider exposure to future share-price appreciation without immediate cash outflow.

Form 4 filing – Inhibikase Therapeutics, Inc. (IKT)

On 06/30/2025, director Dennis N. Berman received 108,176 stock options with an exercise price of $1.95 per share. The grant vests on the earlier of 06/30/2026 or the day prior to the company’s next annual shareholder meeting, subject to continued board service, and expires on 06/30/2032. No common shares were bought or sold in this filing; the reporting person’s beneficial ownership now includes the newly issued options, held directly.

On 07/02/2025, Inhibikase Therapeutics, Inc. (ticker: IKT) submitted a Form 4 detailing an equity incentive granted to director Roberto Bellini. On 06/30/2025 he received a stock-option award for 108,176 common shares at an exercise price of $1.95 per share. The options vest on the earlier of 06/30/2026 or the day prior to the next annual shareholders’ meeting, provided Bellini remains on the board, and expire on 06/30/2032. The filing shows no open-market purchases or sales; the entire position is held directly and recorded at zero acquisition cost. Bellini’s post-transaction derivative holdings therefore total 108,176 options, with no change to his non-derivative share count.

Nasdaq Stock Market LLC has filed Form 25 to remove JVSPAC Acquisition Corp. (symbol: JVSAU) securities from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The filing, dated 30 June 2025 and signed by AVP Tara Petta, covers the company’s Class A Ordinary Shares, Rights, and Units. Nasdaq states that it "has complied with its rules" for striking the securities, indicating that the exchange—not the issuer—initiated the action under Rule 12d2-2(b). Once effective (generally ten days after filing), the securities will no longer trade on Nasdaq and their registration under Section 12(b) will be withdrawn. No financial metrics, earnings information, or business rationale are provided in the document.

The filing is procedurally straightforward but materially important for investors because delisting typically reduces liquidity, transparency, and market visibility. Holders may need to rely on over-the-counter venues—if any quotations develop—or pursue private transfers. The document does not mention concurrent listing on another exchange, merger activity, or compliance remediation efforts, leaving the ultimate future trading venue and corporate strategy unclear.